Characteristics and Clinical Outcomes of Hospitalized Patients with Community-Acquired Pneumonia who are Active Intravenous Drug Users by Salunkhe, Vidyulata et al.
Introduction
Opioid use has reached epidemic proportions in the US with 
the State of Kentucky ranking third in the country for age-
adjusted rates of drug overdose deaths[1]. The highest overdose 
deaths in Kentucky were reported in the city of Louisville [2]. 
Infectious diseases are a major cause of morbidity and mortality 
among intravenous drug users (IVDU)[3-6]. Malnutrition, 
immunodeficiency, homelessness and needle sharing play a 
major role in this groups increased risk.
Community-acquired pneumonia (CAP) is one of the most 
serious infectious complications that has been described in 
IVDU [7-10]. IVDU has also been associated with greater 
severity of CAP which may be evident by the development of 
empyema, complicated parapneumonic effusion, or need of 
mechanical ventilation [11, 12].
Despite the knowledge of IVDU being at increased risk of 
acquiring pneumonia, there are no studies evaluating if 
intravenous drug use is associated with poor outcomes in 
hospitalized patients with CAP. The objectives of this study were 
to compare hospitalized patients with CAP who are active IVDU 
to patients with no history of active IVDU in regards to clinical 
characteristics and clinical outcomes.
Methods
Study Design & Study Population
This was a case control study. The cases, hospitalized patients 
with IVDU, and controls, hospotalized patients without IVDU 
were obtained performing a secondary data analysis of the 
University of Louisville Pneumonia study, a prospective 
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Abstract
Background: Intravenous drug users (IVDU) have a 10-fold increased risk of community-acquired 
pneumonia (CAP) compared to the general population. There is scarce data available evaluating the 
clinical outcomes of IVDU hospitalized patients with CAP and that data mostly focuses on mortality. 
The objective of this study was to evaluate the clinical characteristics, incidence and outcomes of 
hospitalized patients with CAP in active intravenous drug users in Louisville, Kentucky.
Methods: This was a secondary data analysis of the University of Louisville Pneumonia study. 
IVDU patients were propensity score matched to a non-IVDU group. Study outcomes were time to 
clinical stability (TCS), length of stay (LOS), mortality at discharge, and mortality at 1 year. Stratified 
Cox proportional hazard regression was performed to evaluate TCS and LOS. Conditional logistic 
regression was performed to evaluate mortality. Statistical significance was defined as p ≤ 0.05.
Results: From a total of 8,284 hospitalized patients with CAP reviewed, 113 patients were matched 
per group. Median (IQR) age for the IVDU was 33 (28-43) versus 36 (28-48) for the matched non-
IVDU group (p<0.001). Analysis showed no association with TCS (stratified hazard ratio (sHR): 0.81; 
95% CI: 0.58-1.14; p=0.227), LOS (sHR: 0.71; 95% CI: 0.50-1.01; p=0.053), mortality at discharge 
(conditional odds ratio (cOR): 1.67; 95% CI: 0.40-6.97; p=0.484) and mortality at 1 year (cOR: 1.125; 
95% CI: 0.43-2.92; p=0.808).
Conclusions: This study shows that active IVDU hospitalized patients with CAP do not have worse 
outcomes when compared with non-IVDU hospitalized patients with CAP. Patients in the IVDU group 
were significantly younger. Since severity scores commonly used are heavily influenced by age, 
these will not likely be useful tools to assist the physicians with the site for care and management.
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population-based cohort study of all hospitalized adults with 
CAP who were residents in the city of Louisville, Kentucky, from 
June 1st, 2014 to May 31st, 2016 [13].
Inclusion Criteria
Diagnosis of CAP required the presence of criterion A, B, and C:
A. New pulmonary infiltrate on imaging (CT scan or chest 
x-ray) at the time of admission to the hospital.
B. Signs and Symptoms of CAP (at least one of the following):
• New or increased cough
• Fever >37.8°C (100.0°F) or hypothermia <35.6°C 
(96.0°F)
• Changes in WBC (leukocytosis >11,000 cells/mm3, 
left shift > 10% band forms/microliter, or leukopenia 
< 4,000 cells/mm3
C. Working diagnosis of CAP at the time of hospital admission 
with antimicrobial therapy given within 24 hours of 
admission. 
Study Groups
Cases (group 1): Hospitalized patients with CAP with active 
IVDU documented in the medical record. 
Controls (group 2): Hospitalized adults with CAP who did not 
have documentation of actively using intravenous drugs. 
IVDU cases were matched 1:1 to control cases by age, race, and 
history of obesity (body mass index >30), current smoker, active 
alcohol use, chronic obstructive pulmonary disease, congestive 
heart failure, stroke, diabetes mellitus, HIV, renal disease, and 
liver disease. 
Study Variables
• Patients’ characteristics: demographics, medical and social 
history, physical, and laboratory findings were collected if 
documented in the medical records.
• Severity of disease: assessed by the following variables – 
acute altered mental status on admission, need of intensive 
care, ventilatory support, or vasopressor on the day of 
admission, pneumonia severity index risk class IV or V.
• Complications: defined as the presence of persistent 
bacteremia and/or endocarditis.
Study Outcomes
• Time to clinical stability (TCS): A patient was defined as 
clinically stable the day that the following four criteria were 
met: 
1. Improvement in cough and shortness of breath
2. Lack of fever for at least 8 hours
3. Improving leukocytosis (decreased at least 10% from 
the previous day)
4. Tolerating oral intake with adequate gastrointestinal 
absorption
Patients were evaluated daily within the first 7 days of 
hospitalization to determine the day when clinical stability 
was reached.
• Length of hospital stay (LOS): defined in days and 
calculated for each patient as the day of discharge minus 
the day of admission. Patients hospitalized for >14 days 
and patients who died prior to 14 days were censored at 
14 days.
• Mortality: defined as death by any cause 1) during 
hospitalization and 2) at one year after discharge.
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Total Population n=113 n=113  
Demographics
Age, median (IQRa) 33 [28, 43] 36 [28, 48] 0.364
Male sex, n (%) 66 (58) 70 (62) 0.684
Black or African American Race, n (%) 9 (8) 6 (5) 0.593
Medical and Social History, n (%)
BMI ≥ 30 20 (18) 22 (20) 0.864
HIV infection 3 (3) 1 (1) 0.614
Renal disease 17 (15) 10 (9) 0.218
Liver disease 47 (42) 37 (33) 0.215
Congestive heart failure 3 (3) 3 (3) >0.999
Chronic obstructive pulmonary disease 23 (21) 30 (27) 0.346
Stroke 5 (4) 4 (4) >0.999
Current Smoker 100 (89) 103 (91) 0.660
Diabetes mellitus 9 (8) 5 (4) 0.408
Cirrhosis 6 (5) 7 (6) >0.999
Alcohol use 21 (19) 27 (24) 0.416
Nursing home resident 3 (3) 2 (2) >0.999
Hospitalized within 90 days 24 (21) 14 (12) 0.109
IV antibiotics within 90 days 15 (13) 7 (6) 0.116
Home infusion 0 (0) 3 (3) 0.245
Chronic dialysis 3 (3) 0 (0) 0.245
Home wound care 1 (1) 1 (1) >0.999
Oral antibiotics within 30 days 13 (12) 20 (18) 0.258
Neoplastic disease within past year 0 (0) 7 (6) 0.021
Pneumonia vaccination 16 (14) 20 (18) 0.586
Flu vaccination 16 (14) 23 (20) 0.305
Physical Exam Findings, median (IQR)
Temperature (Degrees Celsius) 37 [37, 38] 37 [37, 38] 0.231
Respiratory rate (Breaths/Minute) 24 [20, 30] 20 [20, 26] 0.008
Systolic blood pressure (mmHg) 106 [92, 121] 112 [97, 127] 0.094
Diastolic blood pressure (mmHg) 58 [49, 68] 61 [54, 73] 0.055
Heart rate (Beats/Minute) 116 [106, 131] 113 [97, 125] 0.047
Laboratory Findings, median (IQR)
Serum bicarbonate (mEq/L) 25 [22, 27] 25 [22, 28] 0.611
Blood Urea Nitrogen (mg/dL) 14 [9, 20] 12 [9, 15] 0.077
Serum glucose (mg/dl) 132 [116, 165] 122 [104, 146] 0.012
Hematocrit (%) 36 [33, 40] 38 [34, 42] 0.061
Serum sodium (mEq/L) 136 [133, 139] 137 [134, 140] 0.190
Severity of Disease, n (%)
Acute altered mental status on 
admission 33 (29) 18 (16) 0.026
Need of intensive care on admission 37 (33) 20 (18) 0.014
Need of ventilatory support on 
admission 21 (19) 15 (13) 0.363
Need of vasopressors on admission 6 (5) 3 (3) 0.496
Pleural effusion 19 (17) 21 (19) 0.862
PSI Risk Class IV or Vb 35 (31) 26 (23) 0.231
aIQR: Interquartile range      
bPSI: pneumonia severity index
Statistical Analysis
Descriptive statistics were performed, with comparisons 
between groups analyzed by using a Chi-squared test or Fisher’s 
exact test for categorical data and the Wilcoxon-Mann-Whitney 
U test for continuous data. Kaplan Meier curves were created for 
TCS and LOS. Differences in outcomes adjusting for propensity 
score matching were analyzed using stratified Cox proportional 
hazards regression for TCS and LOS and conditional logistic 
regression for mortality during hospitalization and at one year. 
Differences are reported as stratified hazard ratios (sHR) or 
conditional odds ratios (cOR), respectively.
Results
A total of 113 patients with active IVDU and 113 patients matched 
controls were enrolled in the study.
Patients’ characteristics are shown in Table 1. Significant 
higher rates of acute altered mental status and need of intensive 
care were found in the IVDU group. 
The IVDU group was found to have significantly more persistent 
bacteremia (20% vs. 1%, p < 0.001), significantly more 
endocarditis (14% vs 1%, p < 0.001), and significantly more 
pulmonary emboli (15% vs 1%, p < 0.001) than the non-IVDU 
group. Image characteristics compatible with septic emboli were 
seen in 10% of patients in the IVDU group compared to 0%  in 
the non-IVDU group (p <0.001).
The top two organisms were Staphylococcus aureus (23% [35 
patients] in the IVDU group versus 3% [275 patients] in the non-
IVDU group, p= <0.001) and Streptococcus pneumoniae (3% in 
both groups, p= 0.438) as shown in Table 2. IVDU had higher 
rates of Methicillin-resistant Staphylococcus aureus (MRSA) 
and Methicillin-susceptible Staphylococcus aureus (MSSA) 
among positive cultures, (37% versus 11% and 25% versus 5%, 
respectively). In the IVDU group, MRSA was obtained from 11 
blood cultures, 1 from both blood and sputum cultures and 1 
from bronco alveolar lavage (BAL). Also from the IVDU group 
MSSA was obtained from 5 blood cultures, 6 from both blood 
and sputum cultures and 3 from sputum culture. Among the 
non IVDU group MRSA was obtained from 1 blood culture and 
1 from BAL. From the control group MSSA was obtained from 
1 sputum culture.  Antiocrobial susceptibility patterns of these 
organisms were not collected.
Median (IQR) TCS was 2 (2, 5) days for IVDU group and 2 (1, 
4) days for non-IVDU group (sHR: 0.81; 95% CI: 0.58-1.14; 
p=0.227).  Kaplan-Meier curves for TCS are shown in Figure 1.
Median (IQR) LOS was 5 (2, 9) days for IVDU group and 4 (2, 
6) days for non-IVDU group (sHR: 0.71; 95% CI: 0.50-1.01; 
p=0.053). Kaplan-Meier curves for LOS are shown in Figure 2.
Mortality rates during hospitalization were 4% for IVDU group 
and 3% for non-IVDU group (cOR: 1.67; 95% CI: 0.40-6.97; 
p=0.484). Mortality at one year was 12% for IVDU group and 
14% for non-IVDU group (cOR: 1.125; 95% CI: 0.43-2.92; 
p=0.808).
Discussion
This study shows that IVDU is not associated with poor 
outcomes in hospitalized patients with CAP. The more 
aggressive management that these patients may receive upon 
admission may be the reason for similar outcomes in both 
groups despite differences found in the severity of the disease. 
To our knowledge, this is the first study evaluating clinical 
outcomes in IVDU hospitalized with CAP. 
Active IVDU presented with more severe CAP as evidenced by 
their higher rates of admission to the intensive care unit and 
altered mental status. The higher rates of altered mental status 
could be explained by drug overdose and consequent aspiration. 
Our findings are in concordance with published data indicating 
that active substance abuse is a predictor of more severe 
pneumonia and the need for more intensive management. 
Considering that IVDU patients tend to be younger, as shown 
in our study, scores are heavily influenced by age are those 
commonly used to assess severity at presentation to the hospital. 
These may not be useful tools to assist physicians in care and 
management of IVDU CAP patients.
 
It has been reported that IVDU patients develop more 
complications. In a study evaluating risk factors for 
complicated parapneumonic effusion and empyema, IVDU 
was independently associated with the development of these 
complications [11]. However, in our study, a lower number of 
IVDU presented with pleural effusions/empyema. This could 
be related to a higher percentage of patients with congestive 
heart failure in the non-IVDU group who may have developed 
effusions secondary to this baseline comorbidity and not the 
pneumonia. IVDU commonly developed persistent bacteremia 
and endocarditis, particularly in the tricuspid valve with the 
subsequent septic emboli to the lungs [14-16]. Our study also 
showed higher rates of persistent bacteremia and pulmonary 
embolism, both independently associated with poor outcomes. 
There was a higher percentage of patients with chest images 
compatible with septic emboli. This could indicate that the 
pneumonia is actually a consequence of infective endocarditis 
bringing the relevance of obtaining blood cultures on admission 
to the hospitals and allowing an early identification of this 
population.
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Organism IV 
Drug Users, n (%)
Non IV 
Drug Users, n (%)
Staphylococcus aureus 29 (72) 3 (18)
Streptococcus other 2 (5) 3 (18)
Streptococcus pneumoniae 2 (5) 4 (24)
Streptococcus pyogenes 2 (5) 0 (0)
Enterobacter spp. 1 (2) 0 (0)
Klebsiella pneumoniae 1 (2) 0 (0)
Pseudomonas aeruginosa 1 (2) 0 (0)
Respiratory Syncytial Virus A 1 (2) 0 (0)
Rhinovirus/Enterovirus 1 (2) 2 (12)
Aspergillus spp. 0 (0) 1 (6)
Coronavirus HKU1 0 (0) 1 (6)
Coronavirus OC43 0 (0) 1 (6)
Mycoplasma pneumoniae 0 (0) 1 (6)
Parainfluenza Virus 4 0 (0) 1 (6)
Table 2 Microorganisms isolated
Staphylococcus aureus has been reported as the most commonly 
isolated pathogen in IVDU hospitalized [3]. However, only 
2% of these cases were due to MRSA. Our study shows high 
prevalence of MRSA among IVDU with over 50% of those with 
Staphylococcus aureus as the etiology being MRSA.  Current 
guidelines for the management of CAP list injection drug use 
as a risk factor for Staphylococcus aureus without further 
recommendations regarding coverage for MRSA. [17] If our 
findings are confirmed, empiric therapy against MRSA might 
need to be considered in this population.
Our study has several strengths. The Louisville Pneumonia 
Study was a population-based study that included all 
consecutive hospitalized patients with CAP in the same city for 
a period of 2 years. Lack of exclusion criteria for enrollment 
into the study generates a database with a “real-life” approach 
to CAP management. For each individual case, more than 500 
variables are collected resulting in a comprehensive database. 
This study has also several limitations. First, limitations in 
care (do not resuscitate orders or decisions of not to escalate 
therapy), as well as standard preventive measures known to 
reduce complications (deep venous thrombosis/pulmonary 
embolism prophylaxis, early mobilization, etc.) were not 
captured in the study database. Second, the cause of death 
was not captured in the study database. Third, other variables 
like immunosuppressive conditions, immunosuppressive 
medications or long term steroid use was also not captured. 
Among IVDU group, duration of intravenous drug use was not 
captured which may influence outcomes. Finally, patients were 
defined as having a particular comorbidity if this comorbidity 
was documented in the medical record. Specific information 
related to comorbid diseases (e.g. pulmonary function tests, 
hemoglobin A1c, T cell count) was captured if available in 
the medical record. Antibiotics prior to enrollment were not 
analyzed.
In conclusion, our study shows that IVDU is not associated with 
poor outcomes among hospitalized CAP patients. IVDU patients 
were significantly younger and presented with more severe CAP 
as evidenced by higher rates of admission to the intensive care 
unit and altered mental status. These patients also developed 
significantly higher complications like persistent bacteremia, 
pulmonary emboli and endocarditis. A more aggressive 
management may be needed in this young population in order 
to achieve good outcomes and prevent further complications.
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